Literature DB >> 16191264

[Transplantation of human fetal neural stem cells into cerebral ventricle of the neonatal rat following hypoxic-ischemic injury: survival, migration and differentiation].

Su-qing Qu1, Zuo Luan, Guo-cai Yin, Wan-li Guo, Xiao-hong Hu, Nan-hai Wu, Feng-qing Yan, Yang-ming Qian.   

Abstract

OBJECTIVE: Neonatal hypoxic-ischemic encephalopathy (HIE) harms the lives and health of newborn infants and children severely. Given the absence of effective therapies for HIE, it is important to derive new strategies. Neural stem cells (NSCs) have great potential as a therapeutic tool for the repair of a number of central nervous system disorders that involve cell loss. This study was designed to transplant the neural stem cells derived from human fetal brain (hNSCs) into cerebral ventricle of neonatal rat following hypoxic-ischemic injury and to investigate their survival, migration and differentiation in rat brain.
METHODS: Cells obtained from the forebrain of a 12-week old fetus were cultured in the presence of epidermal growth factor, basic fibroblast growth factor and leukemia inhibitory factor for 11 days. Animal models were built in 7-day-postnatal Wistar rats, 3-days after hypoxia-ischemia (HI), 5 microl suspension containing 5.0 x 10(5) hNSCs was injected into the left cerebral ventricle of each HIE rat by using stereotactic instrument. No immunosuppression therapy was given to the animals. At 1, 2, 4 weeks and 3 months after transplantation, the rats were sacrificed and brain tissues were harvested and were then examined by H-E staining and immunohistochemical analysis.
RESULTS: Implanted cells expressing human nuclear protein (hNP) migrated form the subventricular zone (SVZ) along corpus callosum to the damaged areas, especially to the injured side of cortex and hippocampus. In different areas, the implanted hNSCs differentiated into different cell types which were similar to the host cells. The 85% implanted cells in cortex consisted of hNuc-NF or hNuc-Tublin double positive cells, while in the migratory way, 60% implanted cells differentiated into hNuc-GFAP double positive cells. Compared with the 1-week time point, an increased number of hNP-positive cells were observed at 2-weeks, but the number of these cells greatly decreased at 4-weeks and 3 months.
CONCLUSION: The implanted hNSCs could extensively survive, migrate in the brain of neonatal rat with HIE and could differentiate into neurons and astrocytes in a regionally specific manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16191264

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  5 in total

1.  A clinical study of autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier.

Authors:  Alok Sharma; Hemangi Sane; Nandini Gokulchandran; Pooja Kulkarni; Sushant Gandhi; Jyothi Sundaram; Amruta Paranjape; Akshata Shetty; Khushboo Bhagwanani; Hema Biju; Prerna Badhe
Journal:  Stem Cells Int       Date:  2015-02-18       Impact factor: 5.443

2.  Ultrasound guided neural stem cell transplantation through the lateral ventricle for treatment of cerebral palsy in children.

Authors:  Sheng He; Zuo Luan; Suqing Qu; Xuan Qiu; Daqing Xin; Wenkai Jia; Yanhua Shen; Zehui Yu; Tao Xu
Journal:  Neural Regen Res       Date:  2012-11-15       Impact factor: 6.058

3.  Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial.

Authors:  Liem Thanh Nguyen; Anh Tuan Nguyen; Chinh Duy Vu; Doan V Ngo; Anh V Bui
Journal:  BMC Pediatr       Date:  2017-04-12       Impact factor: 2.125

4.  The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy.

Authors:  Thanh Liem Nguyen; Hoang Phuong Nguyen; Trung Kien Nguyen
Journal:  Health Qual Life Outcomes       Date:  2018-08-14       Impact factor: 3.186

5.  Severe-combined immunodeficient rats can be used to generate a model of perinatal hypoxic-ischemic brain injury to facilitate studies of engrafted human neural stem cells.

Authors:  Stephanie R Beldick; James Hong; Svetlana Altamentova; Mohamad Khazaei; Anisha Hundal; Mohammad-Masoud Zavvarian; Prakasham Rumajogee; Jonathon Chio; Michael G Fehlings
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.